Premium
Dipeptidyl peptidase‐4 inhibitors and angioedema: a class effect?
Author(s) -
Saisho Y.,
Itoh H.
Publication year - 2013
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12134
Subject(s) - angioedema , alogliptin , medicine , vildagliptin , dipeptidyl peptidase 4 , adverse effect , dipeptidyl peptidase , pharmacology , dermatology , diabetes mellitus , endocrinology , biochemistry , enzyme , type 2 diabetes , chemistry
Background Dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs. Case report We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP ‐4 inhibitor, alogliptin. Discussion Our case suggests that there is a difference in the risk of angioedema among DPP ‐4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP ‐4 inhibitors is warranted.